General Information
edit

Website	syntaxin.com
Category	BioTech
Phone	44-(0)-1235-552100
Email
Employees

Offices
edit

Abingdon, GBR

Units 4-10, The Quadrant
Barton Lane
Abingdon, OX14 3YS, GBR

Funding
edit

TOTAL	$71.4M
VENTURE FUNDING TOTAL	$71.4M
Series A, 11/05 Abingworth	$10.4M
Series B, 10/07 SR One Life Sciences Partners Abingworth Johnson & Johnson Development Quest for Growth	$32M
Series C, 11/10 Lundbeckfond Ventures Ipsen Seventure Partners Abingworth SR One LSP BioVentures Johnson & Johnson Development	$29M

Tags
edit

Syntaxin
edit

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company’s proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Milestones
edit

Syntaxin received $29M in Series C funding. (11/11/10)

Posted 11/11/10 at 6:27pm via fiercebiotech.com
Syntaxin received $10.4M in Series A funding. (11/14/05)

Posted 7/3/10 at 1:04am
Syntaxin received $32M in Series B funding. (10/31/07)

Posted 3/11/10 at 7:39pm via syntaxin.com